CA
NZ
UK
AU
IND
US
…
ClearPoint Neuro, Inc., a commercial-stage medical device company, focuses on the development and commercialization of platforms for performing minimally invasive surgical procedures in the brain in the United States. The company offers ClearPoint systems, such as ClearPoint hardware, which includes head fixation frame, computer workstation, and in-room monitor; and ClearPoint disposables, which consist of SmartFrame trajectory device, a hand controller and related accessories, and its SmartFlow Neuro cannula. It also provides ClearPoint software, which guides the physician in surgical planning, device alignment, navigation to the target, and procedure monitoring; ClearPoint Prism Neuro laser therapy system to necrotize or coagulate soft tissue; and IRRAflow system, an active fluid exchange platform. In addition, the company offers consulting services to its pharmaceutical and other medical technology partners, such as benchtop testing, preclinical studies, clinical trial support, regulatory consultation, and translation from the preclinical to the clinical setting. It has licenses and collaboration agreements with Koninklijke Philips N.V., UCB Biopharma SRL, Clinical Laserthermia Systems AB, University of California, San Francisco, and NE Scientific, LLC. The company was formerly known as MRI Interventions, Inc. and changed its name to ClearPoint Neuro, Inc. in February 2020. ClearPoint Neuro, Inc. was incorporated in 1998 and is headquartered in Solana Beach, California.
Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website
A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.
ClearPoint Neuro makes MRI-guided surgical systems and single-use accessories used to plan and perform minimally invasive neurosurgical procedures such as biopsies, deep brain stimulation and laser ablation with real-time MRI guidance. Long-term growth may come from recurring consumable sales, additional indications, expanded clinical data and international expansion. The company's niche imaging platform may provide differentiated exposure to an advanced segment of neurosurgery.
Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Income before tax | -25.48M | -18.91M | -22.09M | -16.43M | -14.41M |
| Net income | -25.54M | -18.91M | -22.09M | -16.54M | -15.32M |
| Selling general administrative | 16.50M | 12.00M | 11.76M | 9.61M | 8.76M |
| Selling and marketing expenses | 16.46M | 14.48M | 12.60M | 9.36M | 6.92M |
| Gross profit | 22.69M | 19.12M | 13.61M | 13.53M | 11.29M |
| Reconciled depreciation | 2.24M | 1.90M | 1.19M | 0.78M | 0.16M |
| Ebit | -24.16M | -19.75M | -22.45M | -16.33M | -13.37M |
| Ebitda | -21.93M | -17.84M | -20.99M | -15.58M | -12.74M |
| Depreciation and amortization | 2.24M | 1.90M | 1.46M | 0.76M | 0.63M |
| Non operating income net other | - | - | - | -0.02M | -0.06M |
| Operating income | -24.16M | -19.75M | -22.45M | -16.33M | -13.37M |
| Other operating expenses | 61.13M | 51.14M | 46.40M | 36.88M | 29.67M |
| Interest expense | 2.39M | 0.52M | 0.39M | 0.08M | 0.97M |
| Tax provision | 0.06M | 0.01M | - | - | - |
| Interest income | 1.21M | 0.87M | 0.39M | - | - |
| Net interest income | -1.18M | 0.87M | 0.38M | -0.08M | -0.97M |
| Income tax expense | 0.06M | -18.91M | 1.29M | 0.10M | 0.91M |
| Total revenue | 36.97M | 31.39M | 23.95M | 20.55M | 16.30M |
| Total operating expenses | 46.86M | 38.87M | 36.06M | 29.86M | 24.66M |
| Cost of revenue | 14.28M | 12.27M | 10.34M | 7.02M | 5.01M |
| Total other income expense net | -1.32M | 0.83M | 0.36M | -0.10M | -1.04M |
| Net income from continuing ops | -25.54M | -18.91M | -21.86M | -16.43M | -14.41M |
| Net income applicable to common shares | - | - | - | -16.43M | -14.41M |
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Total assets | 97.75M | 39.19M | 42.66M | 55.49M | 65.58M |
| Intangible assets | 13.92M | 0.48M | 1.04M | 1.03M | 0.27M |
| Other current assets | 2.06M | 1.68M | 1.18M | 1.72M | 0.51M |
| Total liab | 69.73M | 13.80M | 21.49M | 18.60M | 16.79M |
| Total stockholder equity | 28.02M | 25.39M | 21.17M | 36.89M | 48.79M |
| Deferred long term liab | - | - | - | 0.39M | 0.26M |
| Other current liab | 8.81M | 6.33M | 4.00M | 4.89M | 3.14M |
| Common stock | 0.29M | 0.28M | 0.25M | 0.25M | 0.24M |
| Capital stock | 0.29M | 0.28M | 0.25M | 0.25M | 0.24M |
| Retained earnings | -216.91M | -191.37M | -172.46M | -150.37M | -133.93M |
| Other liab | - | - | - | 0.39M | 0.26M |
| Good will | 7.47M | 0.00M | - | - | - |
| Other assets | - | - | - | 0.58M | 0.64M |
| Cash | 45.92M | 20.10M | 23.14M | 27.61M | 54.11M |
| Total current liabilities | 10.77M | 10.35M | 7.43M | 6.79M | 4.75M |
| Current deferred revenue | - | 2.12M | 2.61M | 1.07M | 0.68M |
| Net debt | 12.31M | -16.54M | -9.20M | -15.63M | -41.83M |
| Short term debt | 0.69M | 0.56M | 0.42M | 0.56M | 0.51M |
| Short long term debt total | 58.23M | 3.57M | 13.94M | 11.99M | 12.28M |
| Other stockholder equity | 239.00M | 216.48M | 193.38M | 187.01M | 182.48M |
| Property plant equipment | - | - | - | 1.26M | 2.78M |
| Total current assets | 63.60M | 33.36M | 36.17M | 51.18M | 61.89M |
| Net tangible assets | - | - | - | 35.86M | 48.52M |
| Short term investments | - | - | 0.00M | 9.87M | - |
| Net receivables | 7.26M | 4.71M | 3.94M | 2.67M | 2.34M |
| Long term debt | 49.08M | - | 9.95M | 9.89M | 9.84M |
| Inventory | 8.36M | 6.86M | 7.91M | 9.30M | 4.94M |
| Accounts payable | 1.26M | 1.34M | 0.39M | 0.27M | 0.43M |
| Accumulated other comprehensive income | 5.64M | - | 0.00M | - | - |
| Common stock total equity | - | - | - | 0.25M | 0.24M |
| Retained earnings total equity | - | - | - | -150.37M | -133.93M |
| Non currrent assets other | 1.70M | 0.25M | 0.49M | 0.58M | 0.64M |
| Non current assets total | 34.15M | 5.83M | 6.49M | 4.31M | 3.69M |
| Capital lease obligations | 9.15M | 3.57M | 3.99M | 2.09M | 2.45M |
| Long term debt total | - | - | - | 9.89M | 9.84M |
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Investments | - | -0.28M | 20.88M | -9.59M | -0.17M |
| Change to liabilities | - | - | - | 1.59M | 1.45M |
| Total cashflows from investing activities | 0.61M | -0.28M | 8.95M | -10.74M | -0.17M |
| Net borrowings | 48.09M | -10.00M | 0.00M | - | - |
| Total cash from financing activities | 50.18M | 6.19M | 0.30M | 0.41M | 46.88M |
| Change to operating activities | - | - | - | -1.76M | -0.76M |
| Net income | -25.54M | -18.91M | -22.09M | -16.43M | -14.41M |
| Change in cash | 26.87M | -3.04M | -4.47M | -26.49M | 34.01M |
| Begin period cash flow | 20.10M | 23.14M | 27.61M | 54.11M | 20.10M |
| End period cash flow | 46.97M | 20.10M | 23.14M | 27.61M | 54.11M |
| Total cash from operating activities | -23.93M | -8.95M | -13.72M | -16.17M | -12.70M |
| Issuance of capital stock | 3.26M | 16.15M | 0.00M | 0.00M | 46.78M |
| Depreciation | 0.98M | 1.90M | 1.51M | 0.78M | 0.69M |
| Other cashflows from investing activities | - | - | 9.67M | -0.89M | - |
| Change to inventory | -0.10M | 0.74M | 1.25M | -4.42M | -1.71M |
| Change to account receivables | -0.27M | -1.21M | -1.80M | -0.21M | 0.63M |
| Sale purchase of stock | - | 0.44M | -0.21M | 0.48M | 0.22M |
| Other cashflows from financing activities | -1.86M | 0.04M | 0.51M | -0.07M | -0.13M |
| Change to netincome | - | - | - | 4.01M | 2.60M |
| Capital expenditures | 0.52M | 0.28M | 0.72M | 1.15M | 0.17M |
| Change receivables | - | - | - | -0.21M | -0.66M |
| Cash flows other operating | - | - | - | -1.25M | -0.60M |
| Cash and cash equivalents changes | - | - | - | -26.49M | 34.01M |
| Change in working capital | -9.81M | 1.40M | -1.40M | -4.29M | -1.68M |
| Stock based compensation | 8.18M | 6.91M | 6.08M | 4.13M | 2.08M |
| Other non cash items | 2.27M | -0.24M | 2.18M | -0.35M | 0.42M |
| Free cash flow | -24.45M | -9.22M | -14.44M | -17.31M | -12.87M |
Sector: Healthcare Industry: Medical Devices
|
Stock Name
|
Change
(USD) |
Price
(USD) |
Trailing
PE (x) |
Forward
PE (x) |
Price Sales
TTM (x) |
Price to Book Value (x)
|
Enterprise Value
to Revenue (x) |
Enterprise Value
to EBITDA (x) |
|---|---|---|---|---|---|---|---|---|
| CLPT Clearpoint Neuro Inc |
0.65 7.19% |
9.69 | - | 12.11 | 8.69 | 11.94 | 9.38 | -7.07 |
| ABT Abbott Laboratories |
-1.78 1.70% |
103.10 | 25.97 | 17.24 | 3.57 | 3.20 | 3.81 | 16.75 |
| MDT Medtronic PLC |
-0.84 0.89% |
93.95 | 26.60 | 15.87 | 3.35 | 2.08 | 3.90 | 14.12 |
| SYK Stryker Corporation |
-4.71 1.54% |
301.42 | 29.23 | 16.86 | 4.18 | 4.51 | 4.63 | 17.16 |
| SEMHF Siemens Healthineers AG |
- -% |
47.55 | 39.57 | 21.32 | 3.01 | 3.29 | 2.95 | 16.92 |
ClearPoint Neuro, Inc., a commercial-stage medical device company, focuses on the development and commercialization of platforms for performing minimally invasive surgical procedures in the brain in the United States. The company offers ClearPoint systems, such as ClearPoint hardware, which includes head fixation frame, computer workstation, and in-room monitor; and ClearPoint disposables, which consist of SmartFrame trajectory device, a hand controller and related accessories, and its SmartFlow Neuro cannula. It also provides ClearPoint software, which guides the physician in surgical planning, device alignment, navigation to the target, and procedure monitoring; ClearPoint Prism Neuro laser therapy system to necrotize or coagulate soft tissue; and IRRAflow system, an active fluid exchange platform. In addition, the company offers consulting services to its pharmaceutical and other medical technology partners, such as benchtop testing, preclinical studies, clinical trial support, regulatory consultation, and translation from the preclinical to the clinical setting. It has licenses and collaboration agreements with Koninklijke Philips N.V., UCB Biopharma SRL, Clinical Laserthermia Systems AB, University of California, San Francisco, and NE Scientific, LLC. The company was formerly known as MRI Interventions, Inc. and changed its name to ClearPoint Neuro, Inc. in February 2020. ClearPoint Neuro, Inc. was incorporated in 1998 and is headquartered in Solana Beach, California.
120 S. Sierra Avenue, Solana Beach, CA, United States, 92075
888 287 9109
172
| Name | Title | Year Born |
|---|---|---|
| Mr. Joseph Michael Burnett | Pres, CEO & Director | 1977 |
| Mr. Danilo D'Alessandro | Chief Financial Officer | 1985 |
| Mr. Mazin Sabra | Chief Operating Officer | NA |
| Ms. Ellisa Cholapranee | Gen. Counsel & Sec. | NA |
| Ms. Jacqueline Keller | VP of Marketing | NA |
| Mr. Joseph Michael Burnett | President, CEO & Director | 1977 |
| Mr. Danilo D'Alessandro | Chief Financial Officer | 1986 |
| Mr. Jeremy Stigall | Chief Business Officer | 1984 |
| Mr. Mazin Sabra | Chief Operating Officer | 1981 |
| Ms. Ellisa Cholapranee | General Counsel & Secretary | NA |
Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.
Download a free report with stock ideas and industry insights for general information.
Download Free Report Now →
Basic Materials
+1.59%
Communication Services
+0.05%
Consumer Cyclical
+0.14%
Consumer Defensive
-0.43%
Energy
-0.03%
Financial Services
+0.19%
Financials
-0.35%
Healthcare
+1.05%
Industrials
+0.67%
Real Estate
-0.25%
Technology
+1.31%
Utilities
+0.32%
Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.
Portfolio
Watchlist
Please wait processing your request...